期刊文献+

入院时高密度脂蛋白胆固醇水平对急性ST段抬高心肌梗死患者结局的影响 被引量:7

Impact of high-density lipoprotein levels at hospital admission on the outcome of patients with acute ST-segment elevation myocardial infarction
原文传递
导出
摘要 目的分析急性ST段抬高心肌梗死(ASTEMI)患者人院时高密度脂蛋白胆固醇(HDL-C)水平对随访一年主要心血管不良事件(MACCE)的影响。方法选取2009年5月至2010年5月辽宁省20家医院1067例症状发作24h内入院并进行血脂检测的ASTEMI患者。观察基线情况、住院时症状、诊断、治疗及检查结果。随访1、6个月和1年的药物使用及MACCE(心源性死亡、非致死性心肌梗死、脑卒中及再次血运重建)。采用Cox比例风险模型分析影响MACCE的独立危险因素。结果根据患者入院时HDL—C水平均值,分为〈1.27mmol/L组587例(低组)和≥1.27mmol/L组489例(高组)。随访1、6个月及1年时低组非致死性心肌梗死发生率显著高于高组(分别为1.4% vs.O.0%,P=0.01;2.8%VS.0.4%,P=0.003;4.8% vs.0.9%,P〈0.001),随访6个月及1年时低组MACCE发生率显著高于高组(分别为18.3% vs.13.7%,P=0.04;23.7% vs.18.1%,P=0.03)。年龄(HR=1.02,95%CI:1.006—1.035,P=0.005)、糖尿病(HR=1.05,95%CI:1.053~2.171,P=0.03)、HDL—C水平(HR=O.56,95%CI:0.340~0.921,P=0.02)是ASTEMI患者1年后发生MACCE的独立危险因素。结论入院时HDL-C水平高的ASTEMI患者随访1年和6个月时的MACCE(主要是非致死性心肌梗死)及1个月时的非致死性心肌梗死发生率显著低于HDL—C水平低的患者,并随时间延长其差异越明显。年龄、糖尿病及HDL-C水平是MACCE的独立危险因素。 Objective To analyze the impact of high-density lipoprotein cholesterol (HDL-C) levels at hospital admission on the incidence of major adverse cardiovascular events (MACCE) in patients with acute ST segment elevation myocardial infarction (ASTEMI). Methods 1067 patients with ASTEMI who were admitted to the 20 hospitals in Liaoning region and with lipid profile tested within the 24 hours of admission from May 2009 until May 2010, were enrolled. Data on basic demographic, clinical, status on admission and method of treatment were collected. Rate on various medical use and MACCE (cardiovascular death, non-fatal myocardial infarction, revascularization and stoke) were compared between the two groups through follow-up observation. Cox proportional hazard analysis was estimation. Results The median HDL-C level was 1.27 mmol/L, with 587 patients having HDL-C below and 489 patients HDL-C above the median level. The incidence rates of non-fatal myocardial infarction and MACCE at one-year follow-up period, was higher in low HDL-C group (4.8% vs. 0.9%, P〈0.001 ;23.7% vs. 18.1%, P=0.03, respectively). At one month follow-up, the incidence rate of non-fatal myocardial infarction was higher in low HDL-C group (1.4% vs. 0.0%, P=0.01 ). At six month follow-up, the incidence rates of non-fatal myocardial infarction and MACCE on one-year follow-up was higher in low HDL-C group (2.8% vs. 0.4%, P= 0.003; 18.3% vs. 13.7%, P=0.04, respectively). Results from Cox proportional hazards analysis indicated that age (HR= 1.02,95%CI: 1.006-1.035, P=0.005), diabetes (HR= 1.05,95%CI: 1.053- 2.171, P=0.03), HDL-C level (HR=0.56,95%CI: 0.340-0.921, P=0.02) were significantly related to the incidence of MACCE. Conclusion The incidence rates of one year and six month MACCE (mainly non-fatal myocardial infarction) and one month non-fatal myocardial infarction were significant higher in patients with low than high HDL-C levels at admission while kept on the ascending along with time. Age, diabetes, HDL-C level were independent risk factors related to the incidence of MACCE.
出处 《中华流行病学杂志》 CAS CSCD 北大核心 2012年第3期332-336,共5页 Chinese Journal of Epidemiology
基金 辽宁省科学技术计划(200822500)
关键词 高密度脂蛋白胆固醇 心肌梗死 急性ST段抬高 主要心血管不良事件 High-density lipoprotein cholesterol Acute ST-segment elevation myocardial infarction Major adverse cardiovascular events
  • 相关文献

参考文献1

二级参考文献22

  • 1Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 2LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 3Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 4Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 5Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 6Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 7Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
  • 8Pitt B, Mancini GB, Ellis SG, Rosrnan HS, Park J-S,McGovem ME. Pravastatin limitaUon of atherosclerosis in the coronary arteries (PLAC Ⅰ): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
  • 9Brown G, Albers J J, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidlowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
  • 10MAAS Study Group. Effect of simvastatin on coronary atheroma: the Multicentre Anti-atheroma Study( MAAS). Lancet. 1994;344:633 -638.

共引文献344

同被引文献67

  • 1张萍.血管重建术后心肌梗死标准更加严格——2012年心肌梗死全球新定义解读[J].中国循环杂志,2012,27(S01):107-109. 被引量:3
  • 2韩雅玲.中国经皮冠状动脉介入治疗指南2012解读[J].中国医学前沿杂志(电子版),2012,4(6):37-40. 被引量:20
  • 3颜红兵,宋莉.缩短从发病到再灌注的延迟时间——2012年欧洲心脏病学会急性ST段抬高心肌梗死治疗指南解读[J].中国循环杂志,2012,27(增刊):113-115.
  • 4Lindberg S,Pedersen S H,Mogelvang R,et al.Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention[J].Journal of the American College of Cardiology,2012,60(4):339-345.
  • 5Thiele H,Raeh J,Klein N,et al.Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction:The Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAI in NSTEMI (LIPSIA-NSTEMI Trial)[J].European Heart Journal,2012,33(16):2035-2043.
  • 6ParkYH,KangGH,SongBG,etal.Factorsrelatedtoprehospi-taltimedelayinacuteST-segmentelevationmyocardialinfarction[J].JournalofKoreanMedicalScience,2012,27(8):864-869.
  • 7SahinarslanA,KocamanSA,BasD,etal.Plasmaneutrophilge-latinase-associatedlipocalinlevelsinacutemyocardialinfarctionandstablecoronaryarterydisease[J].CoronaryArteryDisease,2011,22(5):333-338.
  • 8AlbakerO,ZubaidM,AlsheikhAliAA,etal.Earlystrokefollow-ingacutemyocardialinfarction:incidence,predictorsandoutcomeinsixMiddle-Easterncountries[J].CerebrovascularDiseases,2011,32(5):471-482.
  • 9赵根来,王岚峰,李竹琴.超敏C反应蛋白对急性ST段抬高心肌梗死患者心脏终点事件的预测价值[J].中华急诊医学杂志,2010,19(4):392-396. 被引量:14
  • 10刘洋,刘恒亮,赵友民,白树鸣,郝冬琴,开芸,柴建文,刘灵芝,耿国英.老年急性心肌梗死特点及急诊介入治疗近期疗效分析[J].中国循证心血管医学杂志,2010,2(2):92-94. 被引量:14

引证文献7

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部